SCHEMBL6090523

SCHEMBL6090523

O=C1CCN2c3c1cccc3C(=O)NC2c1ccccc1

nearest known ligand 0.41

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
TNKS2 Q9H2K2 2/20 0.39
HTR2C P28335 3/20 0.38
HTR2B P41595 3/20 0.38
KDM4E B2RXH2 5/20 0.37
ALDH1A1 P00352 2/20 0.37
HTR2A P28223 2/20 0.35
PARP1 P09874 1/20 0.35
TSHR P16473 1/20 0.35
S100A4 P26447 1/20 0.34
HSD17B10 Q99714 2/20 0.34
ADORA3 P0DMS8 1/20 0.34
AR P10275 1/20 0.34
CYP19A1 P11511 1/20 0.34
MAOB P27338 1/20 0.34
MEN1 O00255 1/20 0.34
USP2 O75604 1/20 0.34
NSD2 O96028 1/20 0.34
LMNA P02545 1/20 0.34
POLB P06746 1/20 0.34
MAPT P10636 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6089480 0.88 TNKS2 (0.42) TNKS2HTR2CHTR2BKDM4EALDH1A1
SCHEMBL6091873 0.88 MEN1 (0.42) TNKS2HTR2CHTR2BKDM4EALDH1A1
SCHEMBL6089877 0.88 PARP1 (0.39) HTR2CHTR2BKDM4EALDH1A1PARP1
SCHEMBL6090894 0.87 ATM (0.41) TNKS2HTR2CHTR2BKDM4EALDH1A1
SCHEMBL6091386 0.85 KDM4E (0.40) KDM4EALDH1A1TSHRHSD17B10MEN1
SCHEMBL6092226 0.85 TNKS2 (0.45) TNKS2KDM4EALDH1A1HSD17B10MAOB
SCHEMBL6091636 0.85 PARP1 (0.40) TNKS2HTR2CHTR2BKDM4EALDH1A1
SCHEMBL6089133 0.85 HTR2C (0.36) HTR2CHTR2BKDM4EALDH1A1HTR2A
SCHEMBL6090229 0.85 ALDH1A1 (0.41) HTR2CHTR2BKDM4EALDH1A1HTR2A
SCHEMBL6090378 0.84 KDM4E (0.36) HTR2CHTR2BKDM4EALDH1A1HTR2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20060004028-A1 Novel PARP inhibitor MOCHIDA PHARMACEUTICAL CO., LTD. (JP) 2006-01-05 US disclosed
EP-1582520-A1 NOVEL PARP INHIBITORS MOCHIDA PHARMACEUTICAL CO., LTD. (JP) 2005-10-05 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060004028-A1 Novel PARP inhibitor PARP1, PARP2, PARP11 TNKS2 15/4885HTR2C 3206/4885HTR2B 2595/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.